Sarepta Therapeutics, Inc.

SRPT

US8036071004

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 02:30:00 07/02/2026 am IST			5-day change	1st Jan Change
18.50 ^USD	+8.63%		-9.05%	-14.03%

04/02	Sarepta Therapeutics announces clinical trial application approval for SRP-1005 in Huntington's disease	RE
04/02	Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington's Disease	CI

William Blair Downgrades Sarepta Therapeutics to Market Perform From Outperform

Published on 06/20/2025 at 04:50 pm IST

MT Newswires

Latest news about Sarepta Therapeutics, Inc.

04/02	Sarepta Therapeutics announces clinical trial application approval for SRP-1005 in Huntington's disease	RE
04/02	Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington's Disease	CI
04/02	Sarepta Says New Zealand Regulator Cleared Application for Phase 1 Study of Huntington's Drug Candidate	MT
27/01	Sector Update: Health Care Stocks Advance Late Afternoon	MT
27/01	Sector Update: Health Care Stocks Higher Monday Afternoon	MT
26/01	Sector Update: Health Care	MT
26/01	Sarepta Therapeutics Shares Rise After it Says Duchenne Muscular Dystrophy Patients Show Benefits 3 Years After Treatment	MT
26/01	Sarepta Therapeutics, Inc. - Special Call
26/01	Sarepta Therapeutics Says Duchenne Muscular Dystrophy Patients Show Benefits 3 Years After Treatment	MT
26/01	Sarepta Therapeutics, Inc. Announces Positive Topline Three-Year EMBARK Results Showing EleVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients	CI
26/01	Sarepta's Duchenne gene therapy slows disease progression at three years	RE
26/01	Sarepta's Duchenne gene therapy helps maintain motor function, three-year data shows	RE
24/01	Sarepta Therapeutics to report 3-year topline data from Embark study of Elevidys gene therapy	RE
23/01	Wedbush Raises Price Target on Sarepta Therapeutics to $34 From $32, Keeps Outperform Rating	MT
13/01	Sarepta reconfirms yearly sales floor for Elevidys of $500.0 mln	RE
13/01	Sector Update: Health Care Stocks Lower in Afternoon Trading	MT
12/01	Sarepta Therapeutics, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 through Jan-16-2026
12/01	Sarepta Preliminary Q4, 2025 Net Product Revenue Miss Estimates; Shares Fall	MT
08/01	RBC Raises Price Target on Sarepta Therapeutics to $18 From $16, Keeps Sector Perform, Speculative Risk	MT
07/01	Sarepta Files Trial Application for Huntington's Disease Treatment	MT
07/01	Sarepta Therapeutics, Inc. Announces Submission of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington's Disease	CI
07/01	Sarepta Therapeutics announces submission of clinical trial application for SRP-1005	RE
01/01	Sarepta Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
11/12	Sector Update: Health Care Stocks Mixed Premarket Thursday	MT
11/12	Sarepta Therapeutics Refinances $291 Million in Convertible Senior Notes Due 2027	MT

Chart Sarepta Therapeutics, Inc.

Duration

Period

SRPT: Dynamic Chart

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.

Employees

1,372

Sector

Pharmaceuticals

Calendar

03/03 - Q4 2025 Earnings Release (Projected)

More about the company